Etripamil
Brand names: Cardamyst ยท Active ingredient: Etripamil
In short: CARDAMYST is indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
What is Etripamil used for?
CARDAMYST is indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
Etripamil dosage
Administer as soon as possible after PSVT symptom onset.
Administer CARDAMYST by the nasal route only.
Each CARDAMYST device delivers two sprays for a total of 70 mg.
Recommended Dosage:
Using one nasal spray device, administer one spray into each nostril for a total initial dose of 70 mg. If symptoms persist after 10 minutes, use the second nasal spray device to administer a second dose of one spray into each nostril (70 mg total). Patients and caregivers should call their healthcare provider or seek emergency medical help if symptoms do not improve within 20 minutes after a second dose. Do not exceed 140 mg in a 24-hour period. See Instructions for Use for proper nasal spray technique.
If a full initial dose (i.e., 2 sprays, one in each nostril) is not administered due to device malfunction or misuse, the patient should wait at least 10 minutes before self-administering a second dose, if needed.
How to take Etripamil โ instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).
Important Treatment Instructions
Instruct patients and caregivers on PSVT symptoms and the timing of administration in relation to the onset of the episode of PSVT. Instruct patients and caregivers on what to observe following administration, and what would constitute an outcome requiring medical attention. Instruct patients and caregivers to call their healthcare provider or seek emergency medical help if symptoms do not improve within 20 minutes after a second dose.
Administration Information
Instruct patients and caregivers not to test or prime before use. Instruct patients and caregivers to discard the CARDAMYST device after use.
Lactation
Advise lactating women to pump and discard breastmilk for 12 hours after CARDAMYST administration in order to minimize exposure to a breastfed infant .
Manufactured for: Milestone Pharmaceuticals USA, Inc. 6210 Ardrey Kell Road, Suite 650, Charlotte, NC, 28277
Warnings & precautions
Do not take this medicine if: CARDAMYST is contraindicated in patients with:
Hypersensitivity to CARDAMYST or any of its components.
Heart failure โ New York Heart Association (NYHA) Class II to IV.
Wolff-Parkinson-White (WPW), Lown-Ganong-Levine (LGL) syndromes, or manifest pre-excitation (delta wave) on a 12-lead electrocardiogram (ECG).
Sick sinus syndrome without a permanent pacemaker.
Second degree atrioventricular (AV) Mobitz 2 block or higher degree of AV block.
Because of effects on blood pressure, heart rate, and cardiac conduction, CARDAMYST may cause dizziness and/or syncope, especially in patients with a history of syncope and high-grade AV block or sinus node dysfunction, or those with a history of syncope during an episode of PSVT. In clinical trials, a small percentage of patients (0.4%) experienced clinically significant hypotension during test dosing prior to randomization, which precluded further participation in the study. Patients with a history of hypotensive episodes or those at increased risk for hemodynamic instability should be monitored appropriately when initiating CARDAMYST.
If syncope occurs, patients should be placed in the recumbent position and treated supportively.
Patients should be cautioned about these possible adverse effects and advised to administer CARDAMYST in a sitting position, and in a location where the risk of fall is minimal.
Etripamil side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Risk of syncope
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of CARDAMYST was evaluated using pooled data from double-blind, randomized, placebo-controlled trials including NODE-1, NODE-301 Part 1, RAPID, and RAPID Extension. A total of 321 patients were treated with CARDAMYST in randomized controlled studies.
In the RAPID and RAPID Extension studies, in which patients had the option of self-administering a second dose of CARDAMYST for a perceived episode of PSVT, the majority of patients (65%) self-administered a second dose of CARDAMYST (2x70mg).
In NODE-301 Part 1, RAPID, and RAPID Extension, to assess tolerability, a test dose(s) was given prior to randomization. A small percentage of patients failed the test dose due to hypotension (0.4%) .
The majority of treatment-related adverse reactions reported in clinical studies with CARDAMYST have been related to local reactions to, at, or near the nasal administration site, including the nose, throat, and eyes. These local reactions included nasal discomfort, nasal congestion, throat irritation, oropharyngeal pain, lacrimation, rhinorrhea, bleeding from the nose, upper-airway cough syndrome, and sneezing. โฆ
About this medicine
Etripamil, the active ingredient of CARDAMYST is a calcium channel blocker.
The chemical name of etripamil is benzoic acid, 3-[2-[[(4S)-4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl]methylamino]ethyl]-, methyl ester.
Its molecular weight is 452.59 and its molecular formula is C27H36N2O4.
The structural formula is:
Etripamil is a colorless to slightly yellow oil. Etripamil has a pKa of 8.57 and is very soluble in methyl tert-butyl ether, freely soluble in methanol, dichloromethane and acetone, sparingly soluble in ethanol and hexane, and insoluble in water.
CARDAMYST is a spray intended for nasal administration. Each device of CARDAMYST delivers two metered sprays of etripamil with a total of 70 mg. CARDAMYST contains 350 mg/mL of etripamil and the following inactive ingredients: acetic acid, edetate disodium, sulfuric acid for pH adjustment, and water for injection.
How it works: Etripamil is an L-type calcium influx inhibitor (slow channel blocker or calcium ion antagonist). โฆ
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID a92170b9-4f93-4b83-b2cd-cb85c52821cd. Read the full official label on DailyMed.